Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries

References

• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220
   PubMed Web of Science ®Google Scholar
• Boehringer-Ingelheim. Pradaxa Prescribing Information 2016. Available at: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. accessed May 2017
   Google Scholar
• Janssen. Xarelto Prescribing Information 2017. Available at: https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf. accessed May 2017
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738-46
   PubMed Web of Science ®Google Scholar
• Lip GY, Mitchell SA, Liu X, et al. Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol 2016;204:88-94
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:480-6
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. J Am Coll Cardiol 2016;67(13Suppl1):S692
   Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016;5:e003725
   PubMed Web of Science ®Google Scholar
• Bengtson L, Chen L, MacLehose R, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation. Presented at: American Heart Association’s 2014 Scientific Sessions and Resuscitation Science Symposium, Chicago, Illinois, USA. Circulation 2014;130(Suppl2):A20218
   Google Scholar
• Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;353:i3189
   PubMed Web of Science ®Google Scholar
• Sanfelix-Gimeno G, Rodriguez-Bernal C, Hurtado I, et al. Effectiveness and safety of new and traditional oral anticoagulants in a population-based cohort of new users with atrial fibrillation. Presented at ISPOR 18th Annual European Congress in Milan Italy. Value Health 2015;18:A378
   Google Scholar
• Lin I, Masseria C, Mardekian J, et al. Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records. Poster P6215. European Society of Cardiology (ESC) Congress, 29 August–2 September 2015. Available at: http://congress365.escardio.org/Search-Results?vgnextkeyword=C365PRESENTATION120901#.WWzR2oTytaQ. accessed May 2017
   Google Scholar
• Abraham NS, Sangaralingham LR, Shah ND, et al. Gastrointestinal safety of direct oral anticoagulants: a head-to-head study. Presented at Digestive Disease Week (DDW), San Diego, California, USA. Gastroenterology 2016;150(4Suppl1):S171-S2
   Google Scholar
• Kamble S, Pan X, Phatak H, et al. Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on warfarin versus apixaban 5mg BID, dabigatran 150 mg BID, or rivaroxaban 20 mg QD. Presented at American Heart Association (AHA) Scientific Sessions, Orlando, Florida, USA. Circulation 2015;132(Suppl2):A18465
   Google Scholar
• Al-Khalili F, Lindstrom C, Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin 2016;32:779-85
   PubMed Web of Science ®Google Scholar
• Bouillon K, Bertrand M, Maura G, et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2015;2:e150-9
   PubMed Web of Science ®Google Scholar
• Ellis MH, Neumann T, Ginsberg JS, et al. Bleeding in patients with atrial fibrillation treated with non vitamin K antagonist oral anticoagulants: a population-based study. Presented at: 56th Annual Meeting of the American Society of Hematology, ASH 2014, San Francisco, California, USA. Blood 2014;124:343
   Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016;176:1662-71
   PubMed Web of Science ®Google Scholar
• Zheng Y, Sorensen SV, Gonschior AK, et al. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clin Ther 2014;36:2015-28 e2012
   PubMed Web of Science ®Google Scholar
• Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-68
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Arias E, United States Department of Health and Human Services. National Vital Statistics Reports: United States Life Tables, 2011 2015. Available at: https://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_11.pdf. accessed May 2017
   Google Scholar
• Mercaldi CJ, Siu K, Sander SD, et al. Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fibrillation. Cardiol Res Pract 2012;2012:645469
   PubMedGoogle Scholar
• Bureau of Labor Statistics. Consumer Price Index 2016. Available at: https://www.bls.gov/cpi/. accessed May 2017
   Google Scholar
• Truven Health Analytics Inc. Red Book Online 2016. Available at: http://micromedex.com/products/product-suites/clinical-knowledge/redbook [Last accessed 18 November 2016]
   Google Scholar
• Centers for Medicare and Medicaid Services. Acute Inpatient PPS - FY 2016 IPPS Final Rule Home Page 2016. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page.html [Last accessed 18 November 2016]
   Google Scholar
• Luengo-Fernandez R, Yiin GS, Gray AM, et al. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke 2013;8:308-14
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey 2015. Available at: https://meps.ahrq.gov/mepsweb/data_stats/quick_tables_results.jsp?component=1&subcomponent =0&tableSeries=2&year=-1&SearchMethod=1&Action=Search [Last accessed 18 November 2016]
   Google Scholar
• Centers for Medicare and Medicaid Services. Physician Fee Schedule 2017. Available from: https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched/ [Last accessed 18 November 2016]
   Google Scholar
• Coleman C, Tangirala M, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran and warfarin for stroke prevention in patients with non-valvular atrial fibrillation. Available at http://circ.ahajournals.org/content/132/Suppl_3/A17220. Circulation 2015;132(Suppl3):Abstract 17220
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA275]. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation 2013. Available at: https://www.nice.org.uk/guidance/ta275. accessed May 2017
   Google Scholar
• Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;24:1021-33
   PubMed Web of Science ®Google Scholar
• Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-36
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800-4
   PubMed Web of Science ®Google Scholar
• Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost 2012;108:672-82
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). NICE Technology Appraisal Guidance TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation 2015. Available at: https://www.nice.org.uk/guidance/ta355?unlid=80305033420165282924. accessed May 2017
   Google Scholar
• Canestaro WJ, Patrick AR, Avorn J, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes 2013;6:724-31
   PubMed Web of Science ®Google Scholar
• Harrington AR, Armstrong EP, Nolan PE Jr., et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
   Google Scholar
• Cope S, Clemens A, Hammes F, et al. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials. Value Health 2015;18:234-49
   PubMed Web of Science ®Google Scholar